No Data
No Data
An alternative "going abroad" for centralized procurement of pharmaceuticals and medical devices? The China-ASEAN regional centralized procurement platform for pharmaceuticals has been launched, and the industry anticipates the birth of the first Order.
① Today, the China-ASEAN pharmaceutical regional procurement platform officially launched, with representatives from Shenzhen Mindray Bio-Medical Electronics, United Imaging Healthcare, SIMCERE PHARMA, and other companies present; ② Although the specific implementation plan is yet to be clarified, the industry believes it is undoubtedly Bullish for domestic pharmaceutical companies; ③ The Southeast Asian pharmaceutical market is growing rapidly, but it relies heavily on imported drugs and medical devices.
Shanghai United Imaging Healthcare Co., Ltd. (SHSE:688271) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
CMB International: With continued policy efforts, Bullish on the rebound of China Meheco Group's valuation.
Benefiting from overseas interest rate cuts and improvements in the domestic macro environment, the pharmaceutical sector, as a high-elasticity Industry, is expected to outperform the market in 2025.
Guolian: It is the right time for domestic medical instruments to go global. Focus on leading companies with first-mover advantages in going abroad.
Domestic medical instruments have advantages in production, manufacturing, and upgrades, laying a foundation for products to go global, and the Global medical instruments market has vast potential.
United Imaging Medical (688271.SH): plans to invest 28.4872 million yuan in Asia Vets.
On December 20, Glonghui reported that United Imaging Medical (688271.SH) announced that the company is using 28.4872 million yuan of its own funds to invest in Asia Vets. The Board of Directors has authorized the management to handle matters including but not limited to contract signing and fund disbursement. In this Trade, United Imaging Group intends to acquire a 2.0000% stake in Asia Vets after the capital increase with its own funds, while Shanghai Lianhe plans to acquire a 1.7901% stake in Asia Vets after the capital increase with its own funds. Given that United Imaging Group is the controlling Shareholder of the company, and Shanghai Lianhe directly holds more than 5% of the company's shares, Asia Vets is under the control of the company's controlling Shareholder, United Imaging Group.
Is Shanghai United Imaging Healthcare Co., Ltd. (SHSE:688271) Expensive For A Reason? A Look At Its Intrinsic Value